Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan”In the company’s words, NCT05456880 on ClinicalTrials.gov
- Tested for
- Sickle Cell Disease
- Main trialPhase 1/2
- “This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD”In the company’s words, NCT05456880 on ClinicalTrials.gov
Other drugs for Sickle Cell Disease
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- CTX001Vertex Pharmaceuticals · Phase 3
- L-citrullineAsklepion Pharmaceuticals, LLC · Phase 3
- RilzabrutinibSanofi · Phase 3
- EtavopivatNovo Nordisk · Phase 3
Coming up1
- Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Feb 2028 | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026